首页> 外文OA文献 >P2.04-40 Tumor Mutation Score Is More Powerful Than Tumor Mutation Burden in Predicting Response to Immunotherapy in Non-Small Cell Lung Cancer

【2h】

P2.04-40 Tumor Mutation Score Is More Powerful Than Tumor Mutation Burden in Predicting Response to Immunotherapy in Non-Small Cell Lung Cancer

机译：P2.04-40肿瘤突变评分比肿瘤突变负担更强大，以预测非小细胞肺癌免疫疗法的反应

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Y. Li; Z. Chen; L. Wu; W. Tao;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Tumor mutation score is more powerful than tumor mutation burden in predicting response to immunotherapy in non-small cell lung cancer [J] . Li Yuan, Chen Zuhua, Tao Weiping, Cancer immunology, immunotherapy : . 2021,第8期

机译：肿瘤突变评分比肿瘤突变负担更强大，以预测非小细胞肺癌免疫疗法的反应
2. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer [J] . Negrao Marcelo V., Lam Vincent K., Reuben Alexandre, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2019,第6期

机译：PD-L1表达，肿瘤突变负担和癌症基因突变是从非小细胞肺癌中的HLA I类基因型免受免疫检查点梗死的益处预测因子
3. Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker [J] . Bingxi He, Di Dong, Yunlang She, Journal for ImmunoTherapy of Cancer . 2020,第2期

机译：用肿瘤突变覆荷射系生物标志物预测对晚期非小细胞肺癌免疫疗法的反应
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. The role of NAD(P)H:quinone oxidoreductase 1 in non-small cell lung cancer tumorigenesis and lung cancer stem cell maintenance [D] . Madajewski, Brian. 2016

机译：NAD（P）H：醌氧化还原酶1在非小细胞肺癌的发生和肺癌干细胞维持中的作用
6. Original research: Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker [O] . Bingxi He, Di Dong, Yunlang She, 2020

机译：原始研究：使用肿瘤突变负荷放射生物标记物预测晚期非小细胞肺癌对免疫治疗的反应
7. JCSE01.19 Tumor Mutation Score Is More Powerful Than Tumor Mutation Burden in Predicting Response to Immunotherapy in Non-Small Cell Lung Cancer [O] . Y. Li, Z. Chen, L. Wu, 2019

机译：JCSE01.19肿瘤突变得分比肿瘤突变负担更强大，以预测非小细胞肺癌免疫疗法的反应

P2.04-40 Tumor Mutation Score Is More Powerful Than Tumor Mutation Burden in Predicting Response to Immunotherapy in Non-Small Cell Lung Cancer

著录项

引文网络

相似文献

相关主题

期刊订阅